arrow
F

Firas El Chaer

University of Kansas
H指数:20
被引数:1,648

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia

异基因移植前急性髓系白血病中可测量的残留突变NPM1

2025-11-240
OAAI
Corrigendum to ‘American Society for Transplantation and Cellular Therapy Series #10: Management of Parainfluenza and Human Metapneumovirus Infections in Hematopoietic Cell Transplantation and Cellular Therapy Recipients’ [Transplantation and Cellular Therapy 31 (2025) 624-638/ https://doi.org/10.1016/j.jtct.2025.06.016]

勘误:‘American Society for Transplantation and Cellular Therapy Series #10: Management of Parainfluenza and Human Metapneumovirus Infections in Hematopoietic Cell Transplantation and Cellular Therapy Recipients’ [Transplantation and Cellular Therapy 31 (2025) 624-638/ https://doi.org/10.1016/j.jtct.2025.06.016]

2025-11-190
PRE
ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera
2025-11-011
PRE
American Society for Transplantation and Cellular Therapy Series #10: Management of Parainfluenza and Human Metapneumovirus Infections in Hematopoietic Cell Transplantation and Cellular Therapy Recipients

美国移植与细胞治疗学会系列 #10: 血液细胞移植和细胞治疗受者副流感病毒和人类鼻病毒感染的 Management

2025-06-010
OAAI
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial

一项多中心研究,旨在评估美国和加拿大特发性血小板增多症患者中ropeginterferon alfa-2b-njft的疗效、安全性和耐受性:EXCEED-ET试验

2025-04-170
OA
Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

急性髓系白血病异基因移植前的可测量残留NPM1突变

BLOOD
IF23.1
2024-11-050
PRE
A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

一项关于Nuvisertib(TP-3654)的1/2期研究,Nuvisertib是一种实验性选择性PIM1激酶抑制剂,与JAK抑制剂Ruxolitinib或Momelotinib联合用于骨髓纤维化患者。

BLOOD
IF23.1
2024-11-051
PRE
Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

细胞因子调节与接受Nuvisertib(TP-3654)治疗骨髓纤维化患者的症状改善显著相关,Nuvisertib是一种在研的选择性PIM1激酶抑制剂。

BLOOD
IF23.1
2024-11-050
PRE
American Society of Transplantation and Cellular Therapy Series: #7-Management of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients

美国移植和细胞治疗学会系列: #7-造血细胞移植受者呼吸道合胞病毒感染的管理

2023-12-0110
OAAI
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts
2023-09-017
PRE
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant
2023-03-0775
OA
Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy
2021-01-0159
PREAI
Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes

淋巴瘤嵌合抗原受体T细胞治疗后免疫效应细胞相关神经毒性综合征: 预测性生物标志物和临床结果

2020-08-0558
OAAI